Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRKR 
Marker Therapeutics Inc (MRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MRKR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.05% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.85M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 184465 | Beta 1.52 | 52 Weeks Range 1.10 - 5.99 | Updated Date 04/2/2025 |
52 Weeks Range 1.10 - 5.99 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.22 | Actual -0.42 |
Profitability
Profit Margin -179.71% | Operating Margin (TTM) -124.6% |
Management Effectiveness
Return on Assets (TTM) -41.92% | Return on Equity (TTM) -79.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5913821 | Price to Sales(TTM) 2.38 |
Enterprise Value -5913821 | Price to Sales(TTM) 2.38 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA -0.22 | Shares Outstanding 10709000 | Shares Floating 5437082 |
Shares Outstanding 10709000 | Shares Floating 5437082 | ||
Percent Insiders 9.85 | Percent Institutions 41.81 |
Analyst Ratings
Rating 5 | Target Price 19 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Marker Therapeutics Inc
Company Overview
History and Background
Marker Therapeutics Inc. was founded in 2003. The company focuses on developing novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors.
Core Business Areas
- T Cell Immunotherapy: Marker Therapeutics is developing multi-tumor associated antigen (TAA)-specific T cell therapies that target a broad range of tumor antigens to potentially overcome tumor heterogeneity and antigen escape.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology, oncology, and drug development. The company has a traditional organizational structure with departments focusing on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- MT-401: MT-401 is Marker Therapeutics' lead product candidate, a multi-TAA-specific T cell therapy being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) post allogeneic hematopoietic stem cell transplant (allo-HSCT). Market share data is currently unavailable as it is in clinical trials. Competitors include companies developing CAR-T cell therapies and other immunotherapies for AML, such as Novartis (Kymriah), Kite Pharma (Yescarta), and Celgene (now part of Bristol Myers Squibb).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advancements in T cell therapies and increasing demand for personalized cancer treatments.
Positioning
Marker Therapeutics is positioned as a developer of multi-TAA-specific T cell therapies, which aim to address the limitations of single-target therapies. Their competitive advantage lies in their ability to target multiple antigens, potentially reducing the risk of tumor escape.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to reach billions of dollars. Marker Therapeutics is positioned to capture a portion of this market with their lead product, MT-401, targeting AML.
Upturn SWOT Analysis
Strengths
- Multi-TAA-specific T cell therapy platform
- Potential to overcome tumor heterogeneity and antigen escape
- Focus on underserved patient populations
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of T cell therapy platform to other cancer types
- Advancements in manufacturing and delivery technologies
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles and changing reimbursement landscape
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- GILD
- NVS
Competitive Landscape
Marker Therapeutics faces competition from established pharmaceutical companies developing CAR-T cell therapies and other immunotherapies. While they are smaller compared to these companies, their multi-TAA approach could provide a competitive edge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's growth is dependent on the success of its clinical trials and potential partnerships.
Future Projections: Future growth is dependent on positive clinical trial results and subsequent regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing MT-401 through clinical trials and exploring potential partnerships.
Summary
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T cell immunotherapies. Its multi-TAA approach has the potential to address challenges in cancer treatment, but its success hinges on positive clinical trial outcomes and securing partnerships. The company faces stiff competition and financial constraints, requiring careful management of resources and strategic decision-making to advance its pipeline.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market data is based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Marker Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2014-03-25 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Juan F. Vera M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://markertherapeutics.com |
Full time employees 8 | Website https://markertherapeutics.com | ||
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.